{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:35:18Z","timestamp":1794335718419,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Galectin-3 is a new biomarker, which plays an important role in tissue inflammation, cardiac remodeling, and fibrosis. It can be readily measured in the circulation to detect early heart failure (HF). This study aimed to assess the value of galectin-3 assay in early diagnosis of children with heart failure secondary to congenital heart disease (CHD) and correlate it with the patients\u2019 outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study included 75 children diagnosed to have CHD; {Group A: 45 CHD children with HF symptoms and reduced ejection fraction (REF) and Group B: 30 CHD children with no HF symptoms and normal ejection fraction (NEF)}. They were compared to 40 age- and sex-matched controls (Group C). Children with CHD undergone history taking, Ross HF classification, Echocardiographic assessment and laboratory investigations including serum galactin-3 level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Galectin-3 serum level increased in CHD children, and it showed significant increase in (Gp A) compared to Gp B or Gp C (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2264\u20090.001). In addition, serum level of Galactin-3 was correlated positively with Ross classification (<jats:italic>r\u2009<\/jats:italic>=\u20090.68, <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and negatively correlated to EF% (<jats:italic>r<\/jats:italic>= -0.61, <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.001). Galactin-3 showed better diagnostic value than Ross HF classification in early diagnosis of HF in CHD children with a cut point (\u2265\u200910.4), significantly had 96.7% sensitivity, 90% specificity, 91% positive predictive value, 93.2% negative predictive value, with area under the curve (AUC\u2009=\u20090.96) and 93% accuracy. While there was a significant correlation between Ross HF classification and HF outcome in (Gp A) children (<jats:italic>p<\/jats:italic>\u2009=\u20090.05), we did not find any significant correlation between serum galectin-3 level and HF mortality in same group (<jats:italic>p<\/jats:italic>\u2009=\u20090.08).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Galectin-3 assay is a promising marker for early diagnosis of HF in children with CHD; but it has no role in detecting HF mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-020-02427-9","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:12:56Z","timestamp":1606522376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Nagwan","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-9031","authenticated-orcid":false,"given":"Hany","family":"Abo-Haded","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"issue":"3","key":"2427_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jcdd3030024","volume":"3","author":"JN Timothy","year":"2016","unstructured":"Timothy JN, Susana CP. Stem Cell Therapy and Congenital Heart Disease. J Cardiovasc Dev Dis. 2016;3(3):24. .","journal-title":"J Cardiovasc Dev Dis"},{"issue":"5","key":"2427_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4070\/kcj.2017.0009","volume":"47","author":"K Min-Seok","year":"2017","unstructured":"Min-Seok K, Ju-Hee L, Eung J, et al. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J. 2017;47(5):555\u2013643. .","journal-title":"Korean Circ J"},{"issue":"1","key":"2427_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.hfc.2013.09.017","volume":"10","author":"AC Fahed","year":"2014","unstructured":"Fahed AC, Roberts AE, Mital S, et al. Heart failure in congenital heart disease: a confluence of acquired and congenital. Heart Failure Clinics. 2014;10(1):219\u201327.","journal-title":"Heart Failure Clinics"},{"key":"2427_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","volume":"5","author":"GM Felker","year":"2012","unstructured":"Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HFACTION study. Circ Heart Fail. 2012;5:72\u20138.","journal-title":"Circ Heart Fail"},{"key":"2427_CR5","first-page":"13","volume":"4","author":"F Kramer","year":"2013","unstructured":"Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Res Rep Clin Cardiol. 2013;4:13\u201322.","journal-title":"Res Rep Clin Cardiol"},{"issue":"1","key":"2427_CR6","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.1038\/s41598-018-26115-y","volume":"8","author":"N My-Nhan","year":"2018","unstructured":"My-Nhan N, Yidan S, Donna V, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep. 2018;8(1):8213.","journal-title":"Sci Rep"},{"issue":"10","key":"2427_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.acvd.2013.06.054","volume":"106","author":"N Hrynchyshyn","year":"2013","unstructured":"Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis. 2013;106(10):541\u20136.","journal-title":"Arch Cardiovasc Dis"},{"key":"2427_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2014.10.009","volume":"443","author":"MD Filipe","year":"2015","unstructured":"Filipe MD, Meijers WC, Rogier, van der Veld, et al. Galectin-3 and heart failure: Prognosis, prediction & clinical utility. Clin Chim Acta. 2015;443:48\u201356.","journal-title":"Clin Chim Acta"},{"key":"2427_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00246-012-0306-8","volume":"33","author":"RD Ross","year":"2012","unstructured":"Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol. 2012;33:1295\u2013300.","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"2427_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pedneo.2017.01.001","volume":"58","author":"M Daniele","year":"2017","unstructured":"Daniele M, Fabio V, Marta R, et al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatr Neonatol. 2017;58(4):303\u201312.","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"2427_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1542\/pir.31-1-4","volume":"31","author":"E Madriago","year":"2010","unstructured":"Madriago E, Silberbach M. Heart Failure in Infants and Children. Pediatrics in Review. 2010;31(1):4\u201312.","journal-title":"Pediatrics in Review"},{"issue":"4","key":"2427_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cardfail.2015.10.022","volume":"22","author":"B French","year":"2016","unstructured":"French B, Wang L, Ky B, et al. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. J Card Fail. 2016;22(4):256\u201362.","journal-title":"J Card Fail"},{"issue":"3","key":"2427_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jsha.2017.11.007","volume":"30","author":"D El-Amrousy","year":"2018","unstructured":"El-Amrousy D, Samir H, Hossam H. Prognostic value of homocysteine and highly sensitive cardiac troponin-T in children with acute heart failure. J Saudi Heart Assoc. 2018;30(3):198\u2013204.","journal-title":"J Saudi Heart Assoc"},{"issue":"2","key":"2427_CR14","doi-asserted-by":"publisher","first-page":"634","DOI":"10.18203\/2349-3291.ijcp20180569","volume":"5","author":"B Rubia","year":"2018","unstructured":"Rubia B, Kher A. Anthropometric assessment in children with congenital heart disease. Int J Contemp Pediatr. 2018;5(2):634\u20139.","journal-title":"Int J Contemp Pediatr"},{"key":"2427_CR15","doi-asserted-by":"publisher","first-page":"e000127","DOI":"10.1136\/bmjpo-2017-000127","volume":"1","author":"S Schwartz","year":"2017","unstructured":"Schwartz S, Olsen M, Woo JG, et al. Congenital heart disease and the prevalence of underweight and obesity from age 1 to 15 years: data on a nationwide sample of children. BMJ pediatrics open. 2017;1:e000127.","journal-title":"BMJ pediatrics open"},{"issue":"2","key":"2427_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jjcc.2012.06.013","volume":"60","author":"H Masatsugu","year":"2012","unstructured":"Masatsugu H, Hiroshi O. Heart rate as a target of treatment of chronic heart failure. Journal of cardiology. 2012;60(2):86\u201390.","journal-title":"Journal of cardiology"},{"issue":"5","key":"2427_CR17","first-page":"90","volume":"4","author":"LA Mohammed","year":"2014","unstructured":"Mohammed LA, Gafar HS, Hussien NR, et al. Galectin-3 as early detector of heart failure in children with congenital acyanotic heart disease. Clin Med Diagn. 2014;4(5):90\u20138.","journal-title":"Clin Med Diagn"},{"issue":"2","key":"2427_CR18","first-page":"147","volume":"2","author":"N Iqbal","year":"2012","unstructured":"Iqbal N, Wentworth B, Choudhary R, et al. Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther. 2012;2(2):147\u201364.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"2427_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00246-016-1488-2","volume":"38","author":"A Kotby","year":"2017","unstructured":"Kotby A, Youssef I, Elmaraghy O, et al. Galactin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity. Pediatr Cardiol. 2017;38(1):95\u2013102.","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"2427_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/CIRCHEARTFAILURE.108.827071","volume":"2","author":"G Engstr\u00f6m","year":"2009","unstructured":"Engstr\u00f6m G, Melander O, Hedblad B. Leukocyte Count and Incidence of Hospitalizations Due to Heart Failure. Circ Heart Fail. 2009;2(3):217\u201322.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2427_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1054\/jcaf.2003.10","volume":"9","author":"MG Shlipak","year":"2003","unstructured":"Shlipak MG, Chertow GC, Massie BM. Beware the rising creatinine level. J Card Fail. 2003;9(1):26\u20138.","journal-title":"J Card Fail"},{"issue":"18","key":"2427_CR22","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.clinbiochem.2015.08.007","volume":"48","author":"JW Meeusen","year":"2015","unstructured":"Meeusen JW, Johnson JN, Gray A, et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48(18):1337\u201340.","journal-title":"Clin Biochem"},{"key":"2427_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijcard.2015.07.063","volume":"201","author":"F Numano","year":"2015","unstructured":"Numano F, Shimizu C, Jimenez-Fernandez S, et al. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. Int J Cardiol. 2015;201:429\u2013237.","journal-title":"Int J Cardiol"},{"key":"2427_CR24","doi-asserted-by":"crossref","unstructured":"Berardinis B, Magrini L, Zampini G et al. Usefulness of combining galectin-3 and BIVA assessments in predicting short and long-term events in patients admitted for acute heart failure. Biomed Res Int. 2014;2014(983098):1\u201310.","DOI":"10.1155\/2014\/983098"},{"key":"2427_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/CIRCRESAHA.115.302929","volume":"115","author":"FS Loffredo","year":"2014","unstructured":"Loffredo FS, Nikolova AP, Pancoast JR, et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97\u2013107.","journal-title":"Circ Res"},{"issue":"5","key":"2427_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.acvd.2017.01.008","volume":"110","author":"NB Moussa","year":"2017","unstructured":"Moussa NB, Karsenty C, Pontnau F, et al. Characteristics and outcomes of heart failure-related hospitalization in adults with congenital heart disease. Arch Cardiovasc Dis. 2017;110(5):283\u201391.","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"2427_CR27","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ijcard.2013.03.003","volume":"168","author":"C Zomer","year":"2013","unstructured":"Zomer C, Vaartjes I, van der Velde T, et al. Heart failure admissions in adults with congenital heart disease: risk factors and prognosis. Int J Cardiol. 2013;168(3):2487\u201393.","journal-title":"Int J Cardiol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-020-02427-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T04:15:06Z","timestamp":1606796106000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-020-02427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1186\/s12887-020-02427-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki, ethics approval of the study was granted by Institutional Review Board (IRB) of Menoufia University, Egypt (Proposal code: R.19.12.681). Written consent from parents was obtained for study participation before enrolling the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"537"}}